Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma ...Middle East

SAN FRANCISCO and SUZHOU, China, June 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent and iaso bio jointly announce the nmpa acceptance of the new drug application for equecabtagene autoleucel for the treatment of relapsed and or refractory multiple myeloma was published today ( Monday 06/06/2022 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma )

Also on site :

• Russia-Ukraine war: List of key events, day 1,426
• Rangers’ Cody Bradford Targeting Return In May From Elbow Surgery
• '90s Trash Metal Band Releases New Single Ahead of Farewell Album